SELENON and colorectal carcinoma: SELENON rs4659382 was nominally associated (p = 0.035) in the additive model with an increased risk of CRA and with all advanced neoplasia in the Irish cohort, as observed for CRC (dominant model: p = 0.005) in the EPIC study [10].